Your browser doesn't support javascript.
loading
The impact of canagliflozin on the risk of neuropathy events: A post-hoc exploratory analysis of the CREDENCE trial.
Liao, Jinlan; Kang, Amy; Xia, Chao; Young, Tamara; Di Tanna, Gian Luca; Arnott, Clare; Pollock, Carol; Krishnan, Arun V; Agarwal, Rajiv; Bakris, George; Charytan, David M; de Zeeuw, Dick; Heerspink, Hiddo J L; Levin, Adeera; Neal, Bruce; Wheeler, David C; Zhang, Hong; Zinman, Bernard; Mahaffey, Kenneth W; Perkovic, Vlado; Jardine, Meg J; Smyth, Brendan.
Afiliação
  • Liao J; The George Institute for Global Health, University of New South Wales, Sydney, New South Wales, Australia; Department of Nephrology, Peking University Shenzhen Hospital, Shenzhen, China.
  • Kang A; The George Institute for Global Health, University of New South Wales, Sydney, New South Wales, Australia; Department of Renal Medicine, Prince of Wales Hospital, Sydney, New South Wales, Australia.
  • Xia C; The George Institute for Global Health, University of New South Wales, Sydney, New South Wales, Australia; Department of Radiology and Department of Neurosurgery, West China Hospital, Sichuan University, Chengdu, China.
  • Young T; The George Institute for Global Health, University of New South Wales, Sydney, New South Wales, Australia.
  • Di Tanna GL; The George Institute for Global Health, University of New South Wales, Sydney, New South Wales, Australia.
  • Arnott C; The George Institute for Global Health, University of New South Wales, Sydney, New South Wales, Australia; Department of Cardiology, Royal Prince Alfred Hospital, Sydney Medical School, Sydney, New South Wales, Australia.
  • Pollock C; Kolling Institute of Medical Research, Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia; Royal North Shore Hospital, Sydney, New South Wales, Australia.
  • Krishnan AV; Prince of Wales Clinical School, University of New South Wales, Australia.
  • Agarwal R; Indiana University School of Medicine and VA Medical Centre, Indianapolis, IN, USA.
  • Bakris G; Department of Medicine, University of Chicago Medicine, Chicago, IL, USA.
  • Charytan DM; Nephrology Division, New York University Langone Medical Centre, New York University School of Medicine, New York, NY, USA.
  • de Zeeuw D; Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Centre Groningen, Groningen, The Netherlands.
  • Heerspink HJL; Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Centre Groningen, Groningen, The Netherlands.
  • Levin A; Division of Nephrology, University of British Columbia, Vancouver, British Columbia, Canada.
  • Neal B; The George Institute for Global Health, University of New South Wales, Sydney, New South Wales, Australia; The Charles Perkins Centre, University of Sydney, Sydney, New South Wales, Australia; Imperial College London, London, United Kingdom.
  • Wheeler DC; The George Institute for Global Health, University of New South Wales, Sydney, New South Wales, Australia; Department of Renal Medicine, University College London Medical School, London, United Kingdom.
  • Zhang H; Renal Division of Peking University First Hospital, Beijing, China.
  • Zinman B; Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, University of Toronto, Toronto, Canada.
  • Mahaffey KW; Department of Medicine, Stanford Centre for Clinical Research, Stanford University School of Medicine, Stanford, CA, USA.
  • Perkovic V; Renal Division of Peking University First Hospital, Beijing, China.
  • Jardine MJ; The George Institute for Global Health, University of New South Wales, Sydney, New South Wales, Australia; Concord Repatriation General Hospital, Sydney, New South Wales, Australia; Department of Medicine, Stanford Centre for Clinical Research, Stanford University School of Medicine, Stanford, CA, U
  • Smyth B; The George Institute for Global Health, University of New South Wales, Sydney, New South Wales, Australia; NHMRC Clinical Trials Centre, University of Sydney, Sydney, New South Wales, Australia; Department of Renal Medicine, St George Hospital, Sydney, New South Wales, Australia. Electronic address:
Diabetes Metab ; 48(4): 101331, 2022 07.
Article em En | MEDLINE | ID: mdl-35172198
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doenças Cardiovasculares / Diabetes Mellitus Tipo 2 / Nefropatias Diabéticas / Neuropatias Diabéticas / Inibidores do Transportador 2 de Sódio-Glicose Tipo de estudo: Clinical_trials / Etiology_studies / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doenças Cardiovasculares / Diabetes Mellitus Tipo 2 / Nefropatias Diabéticas / Neuropatias Diabéticas / Inibidores do Transportador 2 de Sódio-Glicose Tipo de estudo: Clinical_trials / Etiology_studies / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article